RGNX - リジェネックスバイオ (REGENXBIO Inc.) リジェネックスバイオ

 RGNXのチャート


 RGNXの企業情報

symbol RGNx
会社名 REGENXBIO Inc (リジェネックスバイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レジェンクスバイオ(REGENXBIO Inc.)は臨床段階のバイオテクノロジー会社である。同社の遺伝子治療製品候補は遺伝子欠損への対処、治療用タンパク質または抗体の生産を可能にするために、遺伝子を細胞に送達するように設計される。同社は代謝性疾患、神経変性疾患及び網膜疾患の治療領域にわたって製品候補を開発する。製品候補であるRGX-314は湿潤加齢性黄斑変性症(湿性AMD)の治療を目的とする。製品候補であるRGX-501はホモ接合性家族性高コレステロール血症(HoFH)の治療を目的とする。同社は2つの重度遺伝的リソソーム蓄積症、ムコ多糖症I型(MPS I)及びムコ多糖症II型(MPS II)の神経学的症状に対処するために、RGX-111とRGX-121等の製品候補を開発する。製品候補は、遺伝子送達プラットフォームであるNAV Technology Platformからウイルスベクターを利用する。   リジェネックスバイオは米国のバイオテクノロジ―企業。主に、組換型アデノウイルス(AAV)遺伝子工学療法の開発、商業化に従事する。AAV遺伝子工学療法では、ウイルス遺伝子はベクタ―を作製、欠損している箇所に治療に有効な遺伝子配列を挿入し、組換型ベクタ―を作製する。同社はAAV7やAAV8など100以上のベクタ―を開発。本社はメリ―ランド州。   REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
本社所在地 9600 Blackwell Road Suite 210 Rockville MD 20850 USA
代表者氏名 Donald J. Hayden ドナルドJ.ヘイデン
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-552-8181
設立年月日 39630
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 139人
url www.regenxbio.com
nasdaq_url https://www.nasdaq.com/symbol/rgnx
adr_tso
EBITDA EBITDA(百万ドル) 73.66900
終値(lastsale) 63.6
時価総額(marketcap) 2054829758.4
時価総額 時価総額(百万ドル) 241.476
売上高 売上高(百万ドル) 175.79800
企業価値(EV) 企業価値(EV)(百万ドル) 1754.982
当期純利益 当期純利益(百万ドル) 78.13000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Regenxbio Inc revenues increased from $7M to $172.4M. Net income totaled $114.8M vs. loss of $36.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Investment Income increase of 36% to $2.1M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.30 to $3.63.

 RGNXのテクニカル分析


 RGNXのニュース

   REGENXBIO Inc (RGNX): Price Now Near $33.19; Daily Chart Shows Downtrend on 50 Day Basis  2021/09/01 15:19:07 ETF Daily News
The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post REGENXBIO Inc (RGNX): Price Now Near $33.19; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .
   REGENXBIO Inc (RGNX): Price Up $0.13 (0.41)% Over Past Day, Up $0.12 (0.38)% Over Past Hour  2021/08/16 15:17:03 ETF Daily News
This is a reversal of the price action on the previous hour, in which price moved down. The post REGENXBIO Inc (RGNX): Price Up $0.13 (0.41)% Over Past Day, Up $0.12 (0.38)% Over Past Hour appeared first on ETF Daily News .
   REGENXBIO Inc. (RGNX) CEO Ken Mills on Q2 2021 Results - Earnings Call Transcript  2021/08/10 03:31:05 Seeking Alpha
   Regenxbio EPS misses by $0.37, beats on revenue  2021/08/09 20:27:07 Seeking Alpha
   REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights  2021/08/09 20:05:00 PR Newswire
ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials for the treatment of wet AMD and DR utilizing in-office suprachoroidal delivery
   Regenxbio EPS misses by $0.37, beats on revenue  2021/08/09 20:27:07 Seeking Alpha
   REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights  2021/08/09 20:05:00 PR Newswire
ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials for the treatment of wet AMD and DR utilizing in-office suprachoroidal delivery
   Regenxbio Q2 Earnings Preview  2021/08/08 21:35:00 Seeking Alpha
   Gene Therapy For Cancer Market: Comprehensive Study Explore Huge Growth in Future | GLIEAD, REGENXBIO, Autolus  2021/07/29 15:07:00 iCrowdNewswire
The Gene Therapy For Cancer market research report added by Report Ocean, is an in-depth analysis of the latest developments, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with []
   Where Do Hedge Funds Stand On Regenxbio Inc (RGNX)?  2021/07/20 12:36:18 Insider Monkey
   REGENXBIO and Abeona update on arbitration of licensing dispute  2021/07/16 16:56:31 Seeking Alpha
   Rare Disease Gene Therapy Market | Expert Opinion PDF | Top 5 Keyplayers- REGENXBIO, Inc., , Oxford BioMedica plc  2021/07/02 04:46:48 OpenPR
Rare Disease Gene Therapy Market report will provide one with overall market analysis, statistics, various trends, drivers, opportunities, restraints, and every minute data relating to the Synthetic Fibers market necessary for forecasting its revenue, factors propelling & growth. The Rare
   REGENXBIO to Participate in Upcoming Investor Conferences  2021/06/09 11:05:00 PR Newswire
ROCKVILLE, Md., June 9, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following June investor conferences, which will each be held in a virtual meeting format: Bank of America 2021 Napa Biopharma Virtual Conference Fireside Chat: Wednesday,
   REGENXBIO to Participate in Upcoming Investor Conferences - June 09, 2021  2021/06/09 00:00:00 BioSpace
REGENXBIO Inc. announced it will participate in the following June investor conferences, which will each be held in a virtual meeting format
   Regenxbio''s Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years  2021/05/14 18:40:58 Business Insider Markets
Regenxbio Inc (NASDAQ: RGNX) has announced a safety update and additional positive interim data from its ongoing Phase 1/2 trial of RGX-121 to treat patients up to 5 years old diagnosed with

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リジェネックスバイオ RGNX REGENXBIO Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)